INTERCEPT PHARMACEUTICALS

OCALIVA is a primary biliary cholangitis (PBC) treatment used with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or alone in adults unable to tolerate UDCA. See Full Prescribing Information and Boxed Warning. Also see efficacy, safety, dosing, and MOA information... The information contained on this site is intended for audiences in the United States only, for audiences outside of the US please refer to www.advanzpharma.com. The content on this site may not apply to non‑U.S. audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

Also known as: Intercept Pharmaceuticals, Inc., OCALIVA